,for, Item ID-
  • #1177614
  • Quidel #M120

Molecular Reagent Lyra® SARS-CoV-2 For BioMerieux NucliSENS easyMAG System or EMAG System / Thermocycler 96 Tests

REAGENT, SARS COV-2 LYRA ASSAYW/CONTROLS (96/EA) D/S

Features

  • The Lyra SARS-CoV-2 Assay with Controls is for use under an FDA EUA:https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations
  • Lyra® SARS-CoV-2 Assay is a real-time RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal, nasopharyngeal (NP), or oropharyngeal (OP) swab specimens from patients suspected of COVID-19 by their healthcare provider
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests
  • More …
  Log In to Order
or

Product Specifications


Features
  • The Lyra SARS-CoV-2 Assay with Controls is for use under an FDA EUA:https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations
  • Lyra® SARS-CoV-2 Assay is a real-time RT-PCR assay intended for the qualitative detection of nucleic acid from SARS-CoV-2 in nasal, nasopharyngeal (NP), or oropharyngeal (OP) swab specimens from patients suspected of COVID-19 by their healthcare provider
  • Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests
  • Positive results do not rule out bacterial infection or co-infection with other viruses; Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status
  • Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities
  • Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions; negative results must be combined with clinical observations, patient history, and epidemiological information
  • The Lyra SARS-CoV-2 Assay is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time PCR and in vitro diagnostic procedures
  • Results in less than 75 minutes after extraction
  • Simplified and uniform workflow with standard pipetting volumes
  • No ice or cooling block required
  • Kit includes vials of 12x8 Master Mix, Rehydration Solution and liquid Process Controls
  • For use with BioMerieux NucliSENS® easyMAG® System or EMAG® System / Applied Biosystems 7500 Fast Dx, Applied Biosystems 7500 Standard, Roche 100 LightCycler 480, Qiagen Rotor-Gene Q, Bio-Rad CFX96 Touch, Thermofisher QuantStudio 7 Pro Thermocyclers
More Information

Professionals Also Viewed